Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Bevacizumab in Advanced NSCLC with EGFR Mutations
NCT01562028Phase 2Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Jun 2012
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of erlotinib, bevacizumab in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Started Jun 2012; status: completed.
02
Drugs
erlotinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01562028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01562028.